Brief: Syros Receives Fast Track Designation From FDA For Tamibarotene

Syros Pharmaceuticals

26/01/2023 12:31

Jan 26 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR
TAMIBAROTENE FOR THE TREATMENT OF HIGHER-RISK MYELODYSPLASTIC
SYNDROME
    * SYROS PHARMACEUTICALS INC - EXPECTS TO COMPLETE PATIENT
ENROLLMENT IN SELECT-MDS-1 IN Q4 OF 2023, WITH PIVOTAL DATA
EXPECTED IN Q3 OF 2024
    * SYROS PHARMACEUTICALS - INITIAL DATA FROM RANDOMIZED
PORTION OF
SELECT-AML-1 PHASE 2 TRIAL EXPECTED IN Q4 OF 2023 AND ADDITIONAL
DATA IN 2024

Source text for Eikon:  ID:nBw6BDtTta 
Further company coverage:  SYRS.O 
 ((Reuters.Briefs@thomsonreuters.com;))